Erlotinib Unknown Status Phase 2 Trials for Neuroendocrine Tumors Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00843531RAD001 and Erlotinib in Patients With Neuroendocrine Tumors